{"id":"sodium-warfarin","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"0.1-0.5","effect":"Warfarin-induced skin necrosis"},{"rate":"1-3","effect":"Nausea"},{"rate":"1-2","effect":"Alopecia"},{"rate":"1-2","effect":"Rash"}]},"_chembl":null,"_dailymed":{"setId":"2cbcc99d-9107-4d39-a1e9-e19305de8b5d","title":"WARFARIN SODIUM (WARFARIN) TABLET [REMEDYREPACK INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin is a coumarin anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase, which is essential for the carboxylation and activation of vitamin K-dependent clotting factors. This results in decreased synthesis of functional factors II, VII, IX, and X, prolonging the prothrombin time and reducing the risk of thromboembolism.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:17.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT04907825","phase":"PHASE4","title":"A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2023-03-13","conditions":"Atrial Fibrillation, Stroke","enrollment":14},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT07471139","phase":"PHASE3","title":"SWITCH: Apixaban vs Vitamin K in HM3","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-06","conditions":"LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding","enrollment":460},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT02108041","phase":"","title":"Personalized Medicine Decision-Making in a Virtual Clinical Setting","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"","conditions":"Deep Vein Thrombosis, Blood Clots","enrollment":196},{"nctId":"NCT06055920","phase":"NA","title":"The PEERLESS II Study","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-11-17","conditions":"Pulmonary Embolism","enrollment":1200},{"nctId":"NCT07441382","phase":"NA","title":"Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Atrial Fibrillation (AF), Stroke, Hemorrhage","enrollment":200},{"nctId":"NCT07246005","phase":"PHASE2","title":"LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-12-01","conditions":"Left Ventricular Thrombus","enrollment":120},{"nctId":"NCT06655376","phase":"PHASE4","title":"Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-10-02","conditions":"Bleeding, Clot Blood","enrollment":128},{"nctId":"NCT07434661","phase":"PHASE3","title":"Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","status":"NOT_YET_RECRUITING","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2026-02","conditions":"Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery","enrollment":120},{"nctId":"NCT07431762","phase":"PHASE4","title":"Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-02-01","conditions":"Valve Replacement Surgery","enrollment":1058},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT07404436","phase":"PHASE4","title":"Rivaroxaban in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-05","conditions":"Idiopathic Membranous Nephropathy","enrollment":134},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT05701917","phase":"NA","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-01-06","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome","enrollment":300},{"nctId":"NCT07388056","phase":"","title":"Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2012-01-01","conditions":"Cancer-associated Thrombosis","enrollment":169},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT06686628","phase":"PHASE1","title":"An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-20","conditions":"Dermatitis Atopic","enrollment":23},{"nctId":"NCT07362030","phase":"PHASE1","title":"Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-04-14","conditions":"Obesity","enrollment":32},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT07349875","phase":"PHASE4","title":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-01","conditions":"Coronary Artery Disease (CAD)","enrollment":3826},{"nctId":"NCT07331389","phase":"PHASE1","title":"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Overweight Subject, Healthy Subjects","enrollment":111},{"nctId":"NCT07330869","phase":"","title":"Warfarin Effects on Male Fertility After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Città di Lecce Hospital, GVM Care & Research","startDate":"2026-02","conditions":"Male Infertility, Heart Valve Disease","enrollment":90},{"nctId":"NCT03636295","phase":"PHASE3","title":"Low INR to Minimize Bleeding With Mechanical Valves Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-09-05","conditions":"Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement","enrollment":2625},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT05891119","phase":"EARLY_PHASE1","title":"Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-06-03","conditions":"Atopic Dermatitis","enrollment":21},{"nctId":"NCT06138184","phase":"NA","title":"Learning Theory Patient Education for Anticoagulants","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2026-04","conditions":"Knowledge, Attitudes, Practice","enrollment":68},{"nctId":"NCT04045093","phase":"PHASE4","title":"Dabigatran for Mitral Stenosis Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-10-22","conditions":"Atrial Fibrillation, Mitral Stenosis","enrollment":370},{"nctId":"NCT07128888","phase":"PHASE1","title":"Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-11-17","conditions":"Obesity or Overweight","enrollment":60},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT07068841","phase":"PHASE1","title":"Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Neurodawn Pharmaceutical Co., Ltd.","startDate":"2025-05-18","conditions":"Pharmacokinetic Profiles, Y-3 for Injection, Drug-drug Interaction","enrollment":24},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT04794348","phase":"PHASE2","title":"Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin","status":"WITHDRAWN","sponsor":"Vascular Solutions LLC","startDate":"2021-05","conditions":"Anticoagulant Reversal","enrollment":""},{"nctId":"NCT02810704","phase":"PHASE4","title":"Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-12","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":18883},{"nctId":"NCT05782270","phase":"PHASE4","title":"Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-11","conditions":"Anticoagulation, Coronary Endarterectomy","enrollment":202},{"nctId":"NCT06975605","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","status":"COMPLETED","sponsor":"GRIN Therapeutics, Inc.","startDate":"2025-05-20","conditions":"Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders","enrollment":18},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT07208695","phase":"","title":"Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2025-10-01","conditions":"Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins","enrollment":40},{"nctId":"NCT03225820","phase":"","title":"Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2017-11-09","conditions":"Information Seeking Behavior","enrollment":1000},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT03910933","phase":"","title":"Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2017-06-30","conditions":"Health Literacy, Anticoagulation","enrollment":248},{"nctId":"NCT06949124","phase":"PHASE1","title":"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-28","conditions":"Endometriosis, Uterine Fibroids, Assisted Reproduction","enrollment":20},{"nctId":"NCT05741385","phase":"NA","title":"A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-10-10","conditions":"Liver Cirrhosis","enrollment":4},{"nctId":"NCT06920056","phase":"PHASE1","title":"A Study of BGM0504 in Overweight or Obese Participants","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2025-03-24","conditions":"Overweight or Obese","enrollment":28},{"nctId":"NCT06075628","phase":"","title":"Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","status":"RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2023-07-24","conditions":"Atrial Fibrillation, Ischemic Stroke, Acute","enrollment":100},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT06696079","phase":"NA","title":"Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation","status":"RECRUITING","sponsor":"Rahul Raj","startDate":"2025-07-07","conditions":"Chronic Subdural Hematoma, Atrial Fibrillation (AF)","enrollment":332},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT07081035","phase":"PHASE4","title":"Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-10","conditions":"Advanced Heart Failure, Left Ventricular Assist Devices, Anticoagulation Treatment","enrollment":94},{"nctId":"NCT07077954","phase":"PHASE1","title":"COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS","status":"COMPLETED","sponsor":"Children Hospital and Institute of Child Health, Lahore","startDate":"2023-01-20","conditions":"Deep Vein Thrombosis (DVT)","enrollment":74},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT07039604","phase":"","title":"Real-World Study of PADN for the Treatment of PAH","status":"RECRUITING","sponsor":"Pulnovo Medical (Wuxi) Co., Ltd.","startDate":"2025-03-19","conditions":"Pulmonary Hypertension, Hypertension, Pulmonary Arterial","enrollment":200},{"nctId":"NCT03087487","phase":"","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":466991},{"nctId":"NCT04972396","phase":"PHASE1","title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-09-15","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":40},{"nctId":"NCT05622500","phase":"NA","title":"Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2022-09-03","conditions":"Chronic Venous Insufficiency, Chronic Venous Thrombosis, Iliac Vein Stenosis","enrollment":12},{"nctId":"NCT06723691","phase":"PHASE1","title":"Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-12-18","conditions":"Type 2 Diabetes","enrollment":57},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT02318342","phase":"NA","title":"Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2014-12","conditions":"Prosthetic Valve Thrombosis","enrollment":3000},{"nctId":"NCT06789588","phase":"PHASE3","title":"Protocol for Improvement of Therapy With Warfarin","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pernambuco","startDate":"2024-10-21","conditions":"Atrial Fibrillation (AF)","enrollment":700},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06289504","phase":"PHASE1","title":"A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Obesity","enrollment":34},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06906861","phase":"","title":"Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal","status":"COMPLETED","sponsor":"Institute of medicine, Maharagjung medical campus","startDate":"2023-11-01","conditions":"Epistaxis","enrollment":284},{"nctId":"NCT04645550","phase":"PHASE4","title":"Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）","status":"COMPLETED","sponsor":"Northern Jiangsu People's Hospital","startDate":"2020-11-22","conditions":"Cirrhosis, Splenectomy; Status, Venous Thrombosis","enrollment":120},{"nctId":"NCT04645537","phase":"","title":"Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2011-07-01","conditions":"Atrial Fibrillation","enrollment":400000},{"nctId":"NCT06844227","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2021-12-01","conditions":"Atrial Fibrillation (AF)","enrollment":1780},{"nctId":"NCT06215430","phase":"PHASE1","title":"A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-01-11","conditions":"Healthy","enrollment":16},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT03556592","phase":"PHASE1","title":"Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-08-13","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT06402851","phase":"PHASE4","title":"Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)","status":"RECRUITING","sponsor":"Hospital Sirio-Libanes","startDate":"2024-12-18","conditions":"Atrium; Fibrillation, Chronic Kidney Diseases","enrollment":1500},{"nctId":"NCT04234698","phase":"","title":"Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-22","conditions":"Atrial Fibrillation","enrollment":2076},{"nctId":"NCT04250116","phase":"PHASE4","title":"Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2020-04-28","conditions":"Atrial Fibrillation","enrollment":960},{"nctId":"NCT06772779","phase":"PHASE1","title":"A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT00291525","phase":"NA","title":"Randomized On-X Anticoagulation Trial","status":"COMPLETED","sponsor":"On-X Life Technologies, Inc.","startDate":"2006-06-06","conditions":"Heart Valve Disease","enrollment":977},{"nctId":"NCT06738992","phase":"PHASE4","title":"Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-11-14","conditions":"Mitral Valve Repair Surgery","enrollment":384},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2019-09-19","conditions":"Intracranial Hemorrhage","enrollment":104},{"nctId":"NCT06278051","phase":"","title":"An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-02-19","conditions":"Venous Thromboembolism","enrollment":320},{"nctId":"NCT04562116","phase":"PHASE2","title":"A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2021-12-08","conditions":"Atopic Dermatitis","enrollment":17},{"nctId":"NCT05795062","phase":"","title":"Treatment Patterns Among Patients With Venous Thromboembolism in the United States","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-10","conditions":"Venous Thromboembolism","enrollment":13945},{"nctId":"NCT06648837","phase":"NA","title":"Microvisk Continuous Blood Donation Study","status":"NOT_YET_RECRUITING","sponsor":"Microvisk Technologies Ltd","startDate":"2025-01-13","conditions":"Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis, Atrial Fibrillation (AF)","enrollment":2500},{"nctId":"NCT03032835","phase":"","title":"Partners Calciphylaxis Biobank","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease","enrollment":300},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT04970576","phase":"PHASE4","title":"Rivaroxaban in Left Ventricular Thrombus","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2021-06-25","conditions":"Acute Coronary Syndrome, Left Ventricular Thrombus","enrollment":261},{"nctId":"NCT04865978","phase":"PHASE2","title":"Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices","status":"COMPLETED","sponsor":"Palak Shah","startDate":"2021-12-14","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT03512080","phase":"","title":"Warfarin Anticoagulation in Patients in Sub-Saharan Africa","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-06-11","conditions":"Cardiovascular Diseases","enrollment":681},{"nctId":"NCT06606275","phase":"","title":"The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis","status":"COMPLETED","sponsor":"Abu Dhabi Health Services Company","startDate":"2024-01-01","conditions":"End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)","enrollment":67},{"nctId":"NCT06645275","phase":"PHASE4","title":"Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-01-01","conditions":"Anticoagulation","enrollment":416},{"nctId":"NCT05995600","phase":"PHASE4","title":"Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-02-20","conditions":"Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"DIARRHOEA"},{"count":16,"reaction":"DYSPNOEA"},{"count":13,"reaction":"ASTHENIA"},{"count":13,"reaction":"ATRIAL FIBRILLATION"},{"count":13,"reaction":"FATIGUE"},{"count":13,"reaction":"NAUSEA"},{"count":12,"reaction":"PNEUMONIA"},{"count":12,"reaction":"THROMBOSIS"},{"count":11,"reaction":"RASH"},{"count":10,"reaction":"DIZZINESS"}],"_approvalHistory":[],"publicationCount":155,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vitamin K antagonists","Oral anticoagulants"],"phase":"marketed","status":"active","brandName":"Sodium warfarin","genericName":"Sodium warfarin","companyName":"University of Padova","companyId":"university-of-padova","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}